Organization | Key Biologics, LLC

Key Biologics, LLC Report issue

For profit Phase 2

Founded: Memphis TN United States (1999)

Status: No NME R&D (1999)

Organization Overview

First Clinical Trial

2006

NCT00338377

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2015

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 2 Trials (6)

aldesleukin (Proleukin) (2 trials)

cyclophosphamide (cytoxan) (2 trials)

dendritic cells (1 trial)

fludarabine (fludara) (2 trials)

mesna (mesnex) (2 trials)

t lymphocytes (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Melanoma (Phase 2)

Skin Neoplasms (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 2
# of Trial APIs: 6